Validation of Circulating Endothelial Cells and Microparticles in Youth
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01508598|
Recruitment Status : Completed
First Posted : January 12, 2012
Last Update Posted : February 1, 2018
|Condition or disease|
|Childhood Obesity Bariatric Surgery Candidate|
Identification and validation of early chronic disease biomarkers in children is of paramount importance especially in the burgeoning arena of pediatric obesity research. Despite the presence of risk factors, few obese children develop overt CVD early in life. However, the pathologic process of CVD begins in the first two decades of life, particularly in the presence of obesity. Because CVD is a cumulative process occurring over time, identifying the earliest signs in order to intervene sooner may have a large impact on slowing its progression. The challenge is identifying which obese youth have early vascular problems. Looking to the vascular endothelium for biomarkers of damage is a reasonable approach because of its prominent role in the origins of atherosclerosis. Endothelial activation is one of the earliest detectable signs of the beginnings of CVD and predicts subsequent atherosclerosis and future cardiovascular events. However, accurately quantifying endothelial health in children has proven to be a major challenge.
Brachial artery FMD is the most commonly-used method to quantify endothelial health in children. However, this technique is not widely applicable, even in the research setting, because it requires specialized equipment and a highly-trained technician. Moreover, results can be highly variable (especially across sites) due to operator dependence and intra-individual fluctuations in endothelial function. More direct measures of endothelial cell biology, such as CEC and EMP, may offer greater precision in characterizing the state of the endothelium and may be especially useful as risk-prediction biomarkers in youth since they are hallmarks of advanced endothelial cell distress, thereby identifying the highest-risk individuals. CEC and EMP have been extensively studied in adults and are associated with vascular diseases, CVD risk factors, and CVD events. Despite being well-validated in adults, CEC and EMP have not been formally evaluated as disease biomarkers in children and adolescents.
Pediatric obesity is an ideal condition in which to validate CEC and EMP as disease biomarkers since adiposity in childhood is associated with CVD, type 2 diabetes mellitus, and premature death later in life. In particular, extreme obesity is an especially high-risk condition associated with significant co-morbidities. Our primary focus in this study will be the evaluation of CEC and EMP as biomarkers of CVD risk, with a goal of validating CEC and EMP for use as vascular endpoints in pediatric research studies. We propose to evaluate the change in levels of CEC and EMP in response to substantial weight loss in adolescents with extreme obesity undergoing elective, clinically-indicated bariatric surgery.
1. Evaluate the effect of substantial weight loss on levels of CEC and EMP in adolescents with extreme obesity.
We hypothesize that levels of CEC and EMP will be significantly reduced following elective, clinically-indicated bariatric surgery in adolescents with extreme obesity. The magnitude of change in CEC and EMP levels will be correlated with the magnitude of weight loss and improvements in CVD risk factors and endothelial function following bariatric surgery.
We will enroll 32 children and adolescents (ages 8-17) who are scheduled for elective bariatric surgery. They will be evaluated prior to their surgery, six months after surgery and twelve months after surgery.
|Study Type :||Observational|
|Actual Enrollment :||390 participants|
|Official Title:||Validation of Circulating Endothelial Cells and Microparticles in Youth|
|Actual Study Start Date :||February 2012|
|Actual Primary Completion Date :||January 2, 2018|
|Actual Study Completion Date :||January 2, 2018|
- Change from Baseline in Circulating Endothelial Cell (CEC) VCAM Expression at 12-months [ Time Frame: Baseline and 12-months ]
- Change from Baseline in Circulating Endothelial Cell (CEC) Enumeration at 12-months [ Time Frame: Baseline and 12 Months ]
- Change from Baseline in Endothelial Microparticle (EMP) VCAM Expression at 12-months [ Time Frame: Baseline and 12 Months ]
- Change from Baseline in Endothelial Microparticle (EMP) Enumeration at 12-months [ Time Frame: Baseline and 12 Months ]
- Change from Baseline in Circulating Endothelial Cell (CEC) VCAM Expression at 6-months [ Time Frame: Baseline and 6-Months ]
- Change from Baseline in Circulating Endothelial Cell (CEC) Enumeration at 6-months [ Time Frame: Baseline and 6-Months ]
- Change from Baseline in Endothelial Microparticle (EMP) VCAM Expression at 6-months [ Time Frame: Baseline and 6-Months ]
- Change from Baseline in Endothelial Microparticle (EMP) Enumeration at 6-months [ Time Frame: Baseline and 6-Months ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01508598
|United States, Minnesota|
|University of Minnesota|
|Minneapolis, Minnesota, United States, 55455|
|Principal Investigator:||Aaron S Kelly, Ph.D.||University of Minnesota - Clinical and Translational Science Institute|